DUBLIN, April 28, 2016 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced that Mr. Sharon Kochan, Perrigo's Executive Vice President and General Manager, International, will have expanded responsibilities that will now include providing leadership and strategic direction to the Company's Branded Consumer Healthcare ("BCH") segment following the resignation of Mr. Marc Coucke, who previously served as Executive Vice President and General Manager of the BCH segment.
Mr. Kochan was named Perrigo's Executive Vice President and General Manager, International in August 2012. He served as Executive Vice President, General Manager of Rx Pharmaceuticals from March 2007 to August 2012 and as Senior Vice President of Business Development and Strategy from March 2005 to March 2007. Prior to joining Perrigo, Mr. Kochan was Vice President, Business Development of Agis Industries (1983) Ltd. from July 2001 until the acquisition of Agis by the Company in March 2005. Mr. Kochan holds a B.Sc. degree in Industrial Engineering, cum laude, from Tel-Aviv University, and a M.Sc. degree in Management Science - Operations Research from Columbia University in the City of New York.
Perrigo's Chief Executive Officer John T. Hendrickson noted, "Sharon's background and ability to drive individuals and organizations to peak performance made my decision to appoint him to lead the BCH team a clear one. Perrigo is well-positioned for a great future, and the BCH team and business are important parts of that future. Perrigo is committed to the long-term prospects for the segment, and I am confident that we have the right team in place to lead and support this growing business during this transition. Aligned with the actions that we are taking to drive improved performance in the BCH segment, we have accepted the resignation of Marc Coucke. The Board and management team wish Marc well in his future endeavors."
Mr. Kochan commented, "I have had the opportunity to get to know the BCH business, including many of its capable leaders and employees, in my current role as Head of International, and I am truly honored to lead such a great business with its impressive pool of talent. Given BCH's expansive distribution platform, strong portfolio of OTC brands, and the entrepreneurial spirit of its employees, I am confident that the business is well-positioned for success and I am very pleased to be a part of that promising future."
Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of branded OTC products, generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides "Quality Affordable Healthcare Products®" across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other key markets including Israel and China. Visit Perrigo online at (http://www.perrigo.com).
Certain statements in this press release are forward-looking statements. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including the timing, amount and cost of share repurchases, and the ability to execute and achieve the desired benefits of announced initiatives. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-KT for the six-month period ended December 31, 2015, as well as the Company's subsequent filings with the SEC, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/perrigo-expands-the-responsibilities-of-sharon-kochan-perrigos-executive-vice-president-and-general-manager-international-to-lead-the-branded-consumer-healthcare-segment-300259171.html
SOURCE Perrigo Company plc